Envestnet Asset Management
PBE icon

Envestnet Asset Management’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Envestnet Asset Management’s Portfolio PBE Stock Details PBE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.69M Buy
21,362
+702
+3% +$56.7K ﹤0.01% 3122
2025
Q4 		$1.7M Buy
20,660
+937
+5% +$72.5K ﹤0.01% 2947
2025
Q3 		$1.38M Buy
19,723
+1,408
+8% +$95.1K ﹤0.01% 3143
2025
Q2 		$1.17M Sell
18,315
-121
-0.7% -$7.5K ﹤0.01% 3180
2025
Q1 		$1.17M Sell
18,436
-1,258
-6% -$84.6K ﹤0.01% 3100
2024
Q4 		$1.31M Sell
19,694
-1,256
-6% -$86.6K ﹤0.01% 2979
2024
Q3 		$1.46M Sell
20,950
-3,497
-14% -$242K ﹤0.01% 2877
2024
Q2 		$1.58M Buy
24,447
+909
+4% +$57.6K ﹤0.01% 2739
2024
Q1 		$1.52M Buy
23,538
+6,084
+35% +$396K ﹤0.01% 2752
2023
Q4 		$1.15M Buy
17,454
+2,124
+14% +$123K ﹤0.01% 2840
2023
Q3 		$874K Buy
15,330
+651
+4% +$39.7K ﹤0.01% 2904
2023
Q2 		$900K Buy
14,679
+3,733
+34% +$233K ﹤0.01% 2826
2023
Q1 		$687K Buy
10,946
+2,518
+30% +$162K ﹤0.01% 2937
2022
Q4 		$535K Sell
8,428
-2,145
-20% -$136K ﹤0.01% 3059
2022
Q3 		$623K Buy
+10,573
New +$651K ﹤0.01% 2880
2022
Q1 		– Sell
-3,354
Closed -$239K – 4025
2021
Q4 		$239K Buy
+3,354
New +$243K ﹤0.01% 3555
2019
Q2 		– Sell
-5,095
Closed -$281K – 3064
2019
Q1 		$281K Buy
+5,095
New +$269K ﹤0.01% 2627
2018
Q3 		– Sell
-2,836
Closed -$155K – 2199
2018
Q2 		$155K Hold
2,836
– – ﹤0.01% 1794
2018
Q1 		$139K Buy
2,836
+143
+5% +$7.29K ﹤0.01% 1790
2017
Q4 		$127K Buy
2,693
+72
+3% +$3.38K ﹤0.01% 2022
2017
Q3 		$131K Sell
2,621
-987
-27% -$46.8K ﹤0.01% 1989
2017
Q2 		$165K Buy
3,608
+1,091
+43% +$47.1K ﹤0.01% 1939
2017
Q1 		$106K Hold
2,517
– – ﹤0.01% 2166
2016
Q4 		$98K Buy
2,517
+635
+34% +$25.6K ﹤0.01% 2188
2016
Q3 		$79K Sell
1,882
-2,955
-61% -$121K ﹤0.01% 2426
2016
Q2 		$179K Buy
4,837
+103
+2% +$4.04K ﹤0.01% 2156
2016
Q1 		$181K Sell
4,734
-13,594
-74% -$528K ﹤0.01% 2122
2015
Q4 		$926K Sell
18,328
-188
-1% -$9.29K ﹤0.01% 1326
2015
Q3 		$847K Buy
18,516
+3,019
+19% +$169K ﹤0.01% 1368
2015
Q2 		$904K Sell
15,497
-242
-2% -$13.8K ﹤0.01% 1443
2015
Q1 		$868K Buy
15,739
+419
+3% +$22.6K ﹤0.01% 1348
2014
Q4 		$769K Sell
15,320
-528
-3% -$25.8K 0.01% 593
2014
Q3 		$733K Sell
15,848
-2,816
-15% -$127K 0.01% 670
2014
Q2 		$816K Sell
18,664
-3,578
-16% -$145K 0.01% 618
2014
Q1 		$926K Buy
22,242
+665
+3% +$28.5K 0.01% 484
2013
Q4 		$799K Buy
21,577
+930
+5% +$33.3K 0.01% 502
2013
Q3 		$724K Buy
20,647
+12,842
+165% +$425K 0.01% 510
2013
Q2 		$225K Buy
+7,805
New +$222K ﹤0.01% 778

Other funds holding PBE

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UCFA
United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
YIA
YHB Investment Advisors West Hartford, Connecticut $1.56B AUM 27.39% 1-Year Est. Return
Cetera Investment Advisers
Cetera Investment Advisers Schaumburg, Illinois $94B AUM 20.14% 1-Year Est. Return

Envestnet Asset Management's PBE Position: Q1 2026 in Review

Envestnet Asset Management increased its Invesco Biotechnology & Genome ETF (PBE) stake by 3.4% in Q1 2026, buying an estimated $56.7K and bringing the position to 21,362 shares worth $1.69M. The position accounts for ﹤0.01% of the portfolio, ranked #3122.

Envestnet Asset Management first reported a position in PBE in Q2 2013 and has held it in 38 quarters since. The position peaked at $1.7M in Q4 2025. 100 funds tracked by Wall St. Rank hold PBE as of Q1 2026.

  • Envestnet Asset Management held 21,362 shares of Invesco Biotechnology & Genome ETF worth $1.69M as of Q1 2026.
  • Envestnet Asset Management bought 702 Invesco Biotechnology & Genome ETF shares in Q1 2026, an estimated $56.7K.
  • Invesco Biotechnology & Genome ETF made up ﹤0.01% of Envestnet Asset Management's portfolio in Q1 2026, its #3122 holding.
  • Envestnet Asset Management first reported a position in Invesco Biotechnology & Genome ETF in Q2 2013 and has held it in 38 quarters since.
  • Envestnet Asset Management's Invesco Biotechnology & Genome ETF position peaked at $1.7M in Q4 2025.
  • 100 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q1 2026.

Based on Envestnet Asset Management's 13F filing for Q1 2026, filed 4 May 2026.